CRNX
CRINETICS PHARMACEUTICALS INData as of 2026 Q2 (06-30) · 13F snapshot
Summary
CRINETICS PHARMACEUTICALS IN (CRNX) is held as common stock by 3 tracked hedge-fund managers, with a combined reported value of ~$94.90M; the largest are Baker Bros. Advisors, Ken Griffin, Steven Cohen. 1 tracked manager also disclosed PUT or CALL positions, reported separately below. This quarter: 1 new, 1 trimmed, 2 closed. 6 public STOCK Act / OGE trade disclosures are on record. Data as of 2026 Q2, from public SEC 13F filings, delayed up to ~45 days.
Attention · LowThis quarter · Cooling
Common-stock holders31 also report options
Congress trades6
Price$84.95vs quarter-end+127.02%
Sectors0
This quarter's moves
Top holderBaker Bros. AdvisorsNew1
Added0
Trimmed / sold3
Common-stock positions
PUT and CALL disclosures are excluded from these holder counts and values.
Value $87.99M0.4% of portfolio2,351,4652026 Q2
| Investor | Value | % of portfolio | Action |
|---|---|---|---|
| Baker Bros. Advisors | $87.99M | 0.4% | Hold |
PUT / CALL disclosures
Reported separately: 13F option values are not common-stock ownership and do not reveal the full strategy or economic exposure.
Value $714.7K— of portfolio19,1002026 Q2
Value $232.0K— of portfolio6,2002026 Q2
| Investor | Value | % of portfolio | Action |
|---|---|---|---|
| Ken GriffinCALL | $714.7K | — | — |
| Ken GriffinPUT | $232.0K | — | — |
Public SEC 13F filings may appear up to 45 days after quarter-end; STOCK Act / OGE trade filings are generally due within 45 days but may be late. Partial data only — research, not investment advice.